ChromaDex (CDXC) Stock Price, News & Analysis

Company Overview

ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products. The company also commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient NIAGEN; NIAGEN as an active ingredient in its consumer products under the TRU NIAGEN name; and Immulina, a spirulina extract with predominant active compounds of Braun-type lipoproteins for supporting human immune function. In addition, it offers phytochemical reference standards, and other research and development services. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, ShopHQ, and other internet marketplaces, as well as specialty retailers and direct healthcare practitioners in the United States. ChromaDex Corporation was founded in 1999 and is headquartered in Los Angeles, California.

Key Stats

• Today's Range: N/A
• 50-Day Range: $5.26 to $8.55
• 52-Week Range: N/A
• Volume: 554,788 shs
• Average Volume: 720,206 shs
• Market Capitalization: $611.50 million
• P/E Ratio: 787.29
• Dividend Yield: N/A
• Price Target: $9.03
• Consensus Rating: Buy

ChromaDex Stock Analysis - MarketRank™

ChromaDex scored higher than 57% of companies evaluated by MarketBeat, and ranked 223rd out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

ChromaDex has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

ChromaDex has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 200.00%

Earnings Growth

Earnings for ChromaDex are expected to grow by 200.00% in the coming year, from $0.04 to $0.12 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of ChromaDex is 787.29, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 21.40.

Price to Earnings Ratio vs. Sector

The P/E ratio of ChromaDex is 787.29, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 21.94.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for CDXC.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

ChromaDex does not currently pay a dividend.

Dividend Growth

ChromaDex does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.0 / 5
• Environmental Score: -1.77

Short Interest

There is no current short interest data available for CDXC.

News and Social Media

• Score: N/A
• News Sentiment: N/A

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, ChromaDex insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 9.64% of the stock of ChromaDex is held by insiders.

Percentage Held by Institutions

Only 15.41% of the stock of ChromaDex is held by institutions.

CDXC Stock Analysis - Frequently Asked Questions

How were ChromaDex's earnings last quarter?

ChromaDex Co. (NASDAQ:CDXC) announced its earnings results on Thursday, October, 31st. The company reported $0.02 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.01 by $0.02. The firm earned $25.58 million during the quarter, compared to analyst estimates of $23.70 million. ChromaDex had a trailing twelve-month return on equity of 4.85% and a net margin of 1.62%.
Read the conference call transcript.

How do I buy shares of ChromaDex?

Shares of CDXC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of ChromaDex own?

Based on aggregate information from My MarketBeat watchlists, some other companies that ChromaDex investors own include Humana (HUM), American Water Works (AWK), Waste Connections (WCN), Voyager Therapeutics (VYGR), The RMR Group (RMR), AUO (AUOTY) and DiamondRock Hospitality (DRH).

Company Calendar

• Last Earnings: 10/31/2024
• Today: 4/19/2025
• Next Earnings (Estimated): 5/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Medicinals & botanicals
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:CDXC
• CIK: 1386570
• Web: www.chromadex.com
• Phone: (310) 388-6706
• Fax: 949-419-0294
• Employees: 120
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $9.03
• High Stock Price Target: $11.00
• Low Stock Price Target: $8.00
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 3 Analysts

Profitability

• EPS (Most Recent Fiscal Year): $0.10
• Trailing P/E Ratio: 787.29
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-4,940,000.00
• Net Margins: 1.62%
• Pretax Margin: 1.62%
• Return on Equity: 4.85%
• Return on Assets: 2.70%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.95
• Quick Ratio: 2.35

Sales & Book Value

• Annual Sales: $99.60 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.38 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 77,750,000
• Free Float: 69,020,000
• Market Cap: $611.50 million
• Optionable: Optionable
• Beta: 2.21